Thérapies de Conversion

Corrigendum: The role of 18F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.

Front Immunol . 2023;14 :1219757

Résumé

[This corrects the article DOI: 10.3389/fimmu.2023.1151967.].

Tous les articles